Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61186/rbmb
en
jalali
1400
5
1
gregorian
2021
8
1
10
2
online
1
fulltext
en
Pre-and Post-Transplant Serum Lactate Dehydrogenase Levels as a Predictive Marker for Patient Survival and Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients
بیوشیمی
Biochemistry
مقالات اصلی
Original Article
<div style="text-align: justify;"><strong><em>Background:</em></strong> The discovery of biomarkers to predict the development of complications associated with hematopoietic stem cell transplantation (HSCT) offers a potential avenue for the early identification and treatment of these life-threatening consequences. Serum lactate dehydrogenase (sLDH) has been identified as a potential biomarker for determining the outcome of allogenic HSCT (allo-HSCT).<br>
<br>
<strong><em>Methods:</em></strong> A retrospective study was performed using data collected from 204 allo-HSCT recipient patients to examine the predictive value of sLDH levels pre- and post-allo-HSCT on patient survival, graft-versus-host-disease (GVHD) incidence, and time to platelet/white blood cells (WBC) engraftment.<br>
<br>
<strong><em>Results:</em></strong> Our findings show that neither pre- (p<em>= </em>0.61) nor post-transplantation (p= 0.55) sLDH levels were associated with GVHD incidence. However, elevated sLDH levels pre- and post-transplantation (≥ 386 and ≥ 409 IU/mL, respectively) were found to be adverse risk factors for patient survival (p= 0.16, p= 0.20, respectively). Furthermore, a median sLDH level≥ 400 IU/mL from day +5 to day +15 post-transplantation had a significant positive association with enhanced time to platelet and white blood cell (WBC) engraftment, compared to patients with sLDH levels < 400 IU/mL (p< 0.001).<br>
<br>
<strong><em>Conclusions:</em></strong> Our data suggests that high sLDH levels pre- and post-allo-HSCT could be considered a predictor of poor patient survival. Furthermore, high levels of sLDH days 5-15 post-allo-HSCT could be associated with improved time to platelet and WBC engraftment; however, this appears to come at the cost of increased mortality risk.</div>
Engraftment, Graft versus host disease, Hematopoietic stem cell transplantation, Lactate dehydrogenase.
204
215
http://rbmb.net/browse.php?a_code=A-10-632-1&slc_lang=en&sid=1
Elham
Roshandel
100319475328460012614
100319475328460012614
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sayeh
Parkhideh
drsayehparkhideh@yahoo.com
100319475328460012615
100319475328460012615
Yes
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Haniyeh
Ghaffari Nazari
100319475328460012616
100319475328460012616
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahshid
Mehdizadeh
100319475328460012617
100319475328460012617
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein
Bonakchi
100319475328460012618
100319475328460012618
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ghazaleh
Sankanian
100319475328460012619
100319475328460012619
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abbas
Hajifathali
100319475328460012620
100319475328460012620
No
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.